beloranib

Small moleculeexperimental

Beloranib is a former drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and its clinical development was led by Zafgen. Drug development was halted in 2016 after deaths during clinical trials. — Wikipedia

Clinical trial activity

8 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 2009 (NCT01028261)

Timeline

2000s

Jan 1, 2009
Earliest Phase 1 Sponsor(trial)

2010s

Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Jan 1, 2014
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Methionine aminopeptidase 2INHIBITOR
METAP2 inhibitor
- Methionine aminopeptidase 2 (METAP2) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@@H]1[C@H](OC(=O)/C=C/c2ccc(OCCN(C)C)cc2)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C

Mol. weight: 499.65 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaBeloranib ↗
ChEMBLCHEMBL4297504 ↗

Also known as

beloranib
beloranib
beloranib
beloranib
ckd732
ckd-732
ckd-732
o-(4-dimethylaminoethoxycinnamoyl)fumagillol
zgn-433
zgn-433
zgn-440
zgn-440

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02324491	Phase 2	Dec 1, 2014	Zafgen, Inc.
NCT02179151	Phase 3	Sep 1, 2014	Zafgen, Inc.
NCT02063295	Phase 2	Apr 1, 2014	Zafgen, Inc.
NCT01818921	Phase 2	Jun 1, 2013	University of Florida, Zafgen, Inc.
NCT01666691	Phase 2	Aug 1, 2012	Q-Pharm, Zafgen, Inc.
NCT01507077	Phase 1	Dec 1, 2011	Q-Pharm, Zafgen, Inc.
NCT01372761	Phase 1	Jun 1, 2011	Q-Pharm, Zafgen, Inc.
NCT01028261	Phase 1	Dec 1, 2009	Zafgen, Inc.

Showing 8 of 8 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Zafgen, Inc.	For profit	8	8	3	2009
Q-Pharm	For profit	3	0	2	2011
University of Florida	Academic/Hospital	1	0	1	2013

3 organizations

Page 1 / 1